Expanding its RNA therapeutics portfolio, Eli Lilly has entered into a collaboration agreement with MiNA Therapeutics to develop small activating RNA (saRNA) candidates for up to five targets. The deal, which is worth up to US$1.25 B, gives Lilly access to MiNA’s RNA activation technology platform that enables the upregulation of proteins by the selective and long-lasting transcriptional activation of a target gene. The Lilly deal comes four months after MiNA agreed to partner with Servier to identify saRNA therapies for neurological diseases.